Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,383.00GBp
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
5,383.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,014,631
52-wk High
5,585.07
52-wk Low
4,260.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.05
Market Cap(Mil.): £68,260.29
Shares Outstanding(Mil.): 1,266.65
Dividend: 133.60
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 32.04 29.97 34.18
EPS (TTM): 1.68 -- --
ROI: 6.20 13.65 13.17
ROE: 21.88 15.43 15.15

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

June 12 Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

Jun 12 2018

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

May 30 2018

AstraZeneca cancer drug hits second goal by extending survival

LONDON AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

May 25 2018

AstraZeneca cancer drug hits second goal by extending survival

LONDON, May 25 AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

May 25 2018

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

May 21 2018

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON, May 21 The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

May 21 2018

UPDATE 1-UK Stocks-Factors to watch on May 21

May 21 Britain's FTSE 100 index is seen opening up 52 points on Monday, according to financial bookmakers, with futures up 0.5 percent ahead of the cash market open.

May 21 2018

UK Stocks-Factors to watch on May 21

May 21 Britain's FTSE 100 index is seen opening up 52 points on Monday, according to financial bookmakers. * BRITAIN ECONOMY: British households became much cheerier about their financial situation this month, according to a survey on Monday that will hearten Bank of England officials who think the economy's weak start to the year was temporary. * DRAX: British power company Drax will start work this month on a pilot bioenergy carbon capture and storage (CCS) project

May 21 2018

AstraZeneca pay report rejected by 35 percent of shareholders

LONDON More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

May 18 2018

AstraZeneca pay report rejected by 35 pct of shareholders

LONDON, May 18 More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

May 18 2018

Earnings vs. Estimates